Clinical trials: Allogeneic Transplantation
Bone Loss in Jaw
Demineralized Bone Allograft Fibers Versus Particulate In Sinus Augmentation
The purpose of this clinical trial is to assess if the addition of DFDBA fibers to DBBM results in greater vital bone formation than the addition of DFDBA particles to DBBM.
- Trial name
- NCT06173791
- Testing
- DFDBA fibers, DFDBA particles, DBBM
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause.
- Conditions
- Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
- Trial name
- NCT03922724
- Testing
- ATL-RIC, mRIC, allo HCT
- Where
- 2 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.
- Conditions
- Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases
- Trial name
- NCT00619879
- Testing
- Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
COPD
Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease
This trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in combination with standard COPD medication…
- Trial name
- NCT04433104
- Testing
- Umbilical Cord Mesenchymal Stem Cells transplantation, drug therapy according to Vietnamese MOHS procedure
- Where
- Vietnam
- Volunteers
- 40 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
Allo-SCT Patients, Adult Allo-SCT Survivor
Web-based Patient Education Program to Manage Side Effects of Allogeneic Stem Cell Transplant
The purpose of this study is to develop an interactive web-based patient education program to help educate patients about the increased risk of MS and its cardiac risk factors following allo-SCT and to inform and motivate…
- Trial name
- NCT02812082
- Testing
- web-based patient education, questionnaire
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
This phase Ib trial studies the side effects of combination chemotherapy and donor stem cell transplant followed by ixazomib citrate maintenance therapy in treating patients with multiple myeloma that has returned after a period…
- Trial name
- NCT02504359
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Hematological Diseases
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
- Trial name
- AlloCare (NCT06281496)
- Testing
- AlloCare
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Transplant Rejection
Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
The goal of this observational study is to develop and validate a molecular heart rejection diagnostic system based on targeted transcriptome as a novel monitoring companion tool for heart allograft precision diagnostics…
- Trial name
- Nano-Heart (NCT06436027)
- Testing
- Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 496 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Diabetes
UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes
The aim is to Investigate the safety and efficacy of Portal vein infusion Allogeneic Human umbilical cord mesenchymal stem cells combined with Allogeneic islet transplantation for the treatment of diabetes
- Trial name
- NCT06751199
- Testing
- human umbilical cord mesenchymal stem cells, allogeneic islet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Acute Graft Versus Host Disease
Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment
Graft-versus-host disease is a complication of allogeneic hematopoietic cell transplantation with high morbidity and mortality. The standard treatment is corticosteroids, and based on the response within 3 to 7 days, a…
- Trial name
- NCT06904599
- Testing
- Human chorionic gonadotropin (hCG), Prednisone, Dexamethasone
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Relapsed Acute Myeloid Leukaemia
Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation
In this phase 1 clinical trial, the investigators are testing an experimental medicine in children aged 6 months up to 16 years with acute myeloid leukaemia (AML), which has come back (relapsed).
- Trial name
- CARAML (NCT05942599)
- Testing
- Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00014508
- Testing
- sargramostim, cyclophosphamide, cyclosporine
- Where
- 12 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Diabetic Foot Ulcer
AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers
This is a multicenter, randomized, parallel-group study comparing the outcomes associated with the use of AMNIOEXCEL Plus Placental Allograft Membrane, a marketed comparator and SOC alone in the management of diabetic foot ulcers…
- Trial name
- NCT03547635
- Testing
- AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 116 people
- Sponsor
- Integra LifeSciences Corporation
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
This is a multi-center, phase I/II clinical trial for patients who have relapsed more than 60 day after allogeneic transplant for a hematologic malignancy. The study consists of two phases.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma
- Trial name
- NCT01885897
- Testing
- ALT-803
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Oral Mucositis
Photobiomodulation for the Prevention of Oral Mucositis
The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation.
- Trial name
- NCT07290413
- Testing
- Photobiomodulation - INTRAORAL, Photobiomodulation - EXTRAORAL, Photobiomodulation - INTRAORAL and EXTRAORAL
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Brigham and Women's Hospital
Acute Myeloid Leukemia
Randomized Clinical Study Assessing Haplo vs. URD in AML
This study compares haplo-identical family donor stem cell transplantation (haplo SCT) to matched unrelated donor transplantation (URD SCT) in adult patients with acute myeloid leukemia (AML) with the hypothesis that haplo SCT is…
- Trial name
- NCT04067180
- Testing
- allogeneic stem cell transplantation with a haplo-identical family donor graft, allogeneic stem cell transplantation with a matched unrelated donor graft
- Where
- 9 sites in Austria, Canada and 3 more
- Volunteers
- 18 people
- Sponsor
- Karolinska Institutet
Acute Leukemia
Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia
Intravenous Busulfan (iv-Bu) is commonly used as part of preparation regimen for allogeneic hematopoietic stem cell transplantation for patients with acute leukemia.
- Trial name
- NCT01498016
- Testing
- Busulfan
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
GVHD
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
This is a single arm open label phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from matched-related or unrelated donor are eligible for the study if they meet the standard…
- Trial name
- NCT03945591
- Testing
- Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Acute Myeloblastic Leukemia, Lymphoblastic Leukemia
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
The purpose of this study is to compare Reduced Intensity Conditioning protocols containing either Thymoglobuline or Alemtuzumab in patients undergoing allogeneic transplant from voluntary unrelated donors.
- Conditions
- Acute Myeloblastic Leukemia, Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- GLOBAL (NCT00354120)
- Testing
- Alentuzumab, Globulina antilinfocitaria
- Where
- 22 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo